Send to

Choose Destination
Oncotarget. 2015 Aug 14;6(23):19393-404.

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.

Sui X1,2,3, Ma J4, Han W1,2, Wang X1,2, Fang Y1,2, Li D1, Pan H1,2,3, Zhang L3,5.

Author information

Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
Department of Immunology, University of Toronto, Toronto, ON, Canada.
Department of Gastrointestinal Surgery, Nankai Hospital, Nankai District, Tianjin, China.
Transplantation Institute and Toronto General Research Institute, University Health Network, Toronto, ON, Canada.


The programmed death-1 (PD-1), a coinhibitory receptor expressed on activated T cells and B cells, is demonstrated to induce an immune-mediated response and play a critical role in tumor initiation and development. The cancer patients harboring PD-1 or PD ligand 1 (PD-L1) protein expression have often a poor prognosis and clinical outcome. Currently, targeting PD-1 pathway as a potential new anticancer strategy is attracting more and more attention in cancer treatment. Several monoclonal antibodies against PD-1 or PD-L1 have been reported to enhance anticancer immune responses and induce tumor cell death. Nonetheless, the precise molecular mechanisms by which PD-1 affects various cancers remain elusive. Moreover, this therapy is not effective for all the cancer patients and only a fraction of patients respond to the antibodies targeting PD-1 or PD-L1, indicating these antibodies may only works in a subset of certain cancers. Thus, understanding the novel function of PD-1 and genetic determinants of response to anti-PD-1 therapy will allow us to develop a more effective and individualized immunotherapeutic strategy for cancer.


PD-1; PD-L1; cancer; checkpoint inhibitor; immunotherapy

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center